YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new r…
BioAge Labs, Inc. EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic disea…
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option progra…
New approvals for Leqembi® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to M…
(RTTNews) - BioAge Labs, Inc. (BIOA), a clinical-stage biopharmaceutical company, reported second-quarter financial results reflecting a wider net loss despite a marginal increase in collaboration-based revenue. BioAge develops therapeutic…
[Abstract stock market chart with multicolored candlestick patterns and numeric overlays on a dark background. Concept for trading, investing, cryptocurrency markets and digital economy presentations.] vadishzainer/iStock via Getty Images…
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients w…
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 16 that BIOA announced the dosing of th…
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC…
As European markets experience an upswing, with the pan-European STOXX Europe 600 Index rising by 3% amid hopes for geopolitical de-escalation, investors are keenly observing companies that exhibit both growth potential and significant ins…
The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index ending the week down amid geopolitical tensions and rising energy costs that could lead to inflationary pressures. Despite these headwinds, rob…
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now. TheFly reported on May 13 that BIOA received newly initiated c…
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for ini…
Key Points Initiated new BTGO stake with 12,538,608 shares; estimated trade value of $138.91 million based on quarterly average pricing Quarter-end value of the BTGO position was $103.19 million, reflecting both trading activity and stock…
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keefe, Bruyette & Woods analyst Alex…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Leerink upgraded Johnson & Johnson(JNJ) to…
Quick Read: The April inflation spike hit stocks hard, as only the Dow Jones Industrial Average finished Tuesday modestly higher. With inflation at its highest level in over 3 years, it’s unlikely the Federal Reserve will cut interest rate…
STOCKHOLM, May 8, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biol…
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Hut 8 Corp (Symbol: HUT), where a total of 71,516 contracts have traded so far, representing approximately 7.2 million underlying…
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four lea…
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial i…
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bio…
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at the company's year-to-date performance…
BioAge Labs Inc. (NASDAQ:BIOA) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 10, Citi maintained a Buy rating on BioAge Labs Inc. (NASDAQ:BIOA). The firm significantly increased its pric…
* BioAge Labs press release [https://seekingalpha.com/pr/20448840-bioage-labs-reports-full-year-2025-financial-results-and-provides-business-updates-from-the] (BIOA [https://seekingalpha.com/symbol/BIOA]): FY GAAP EPS of -$2.24 beats by $0…
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biol…
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for s…
[Young female scientist working in laboratory] Solskin Pharmaceutical (PJP [https://seekingalpha.com/symbol/PJP]), (XPH [https://seekingalpha.com/symbol/XPH]), (PPH [https://seekingalpha.com/symbol/PPH]) and biotechnology stocks (XBI [http…
STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early Alzheimer's disease with Leqembi (lecan…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Why BioArctic is on investors’ radar today BioArctic (OM:BIOA B) has recently drawn attention without a clear single news ca…
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) fo…
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the…
[$10 Banknote Stacking, Green Up Arrow Rise] spawns Shares of BioAge Labs (BIOA [https://seekingalpha.com/symbol/BIOA]) continued to spike for the second consecutive session on Tuesday in reaction to updated results from an early-stage tri…
BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly. Continue Reading
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants…
Key Points BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area. 10 stocks we like better than BioAge Labs › BioAge Lab…